Currently, five types of CAR-T cells targeting CD19 have been approved by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies (20), opening up new directions for tumor immunotherapy and antitumor treatment. This evidence concerns the gene CD19 and hematologic disorder.